<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">russjcardiol</journal-id><journal-title-group><journal-title xml:lang="ru">Российский кардиологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Journal of Cardiology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1560-4071</issn><issn pub-type="epub">2618-7620</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1560-4071-2024-5994</article-id><article-id custom-type="edn" pub-id-type="custom">DQKAPQ</article-id><article-id custom-type="elpub" pub-id-type="custom">russjcardiol-5994</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>МИОКАРДИТЫ, КЛАПАННЫЕ И НЕКОРОНАРОГЕННЫЕ ЗАБОЛЕВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>MYOCARDITISES, VALVULAR AND NONCORONAROGENIC DISEASES</subject></subj-group></article-categories><title-group><article-title>Клинические, морфологические и генетические характеристики пациентов молодого возраста с гипертрофической кардиомиопатией, имеющих показания к имплантации кардиовертера-дефибриллятора</article-title><trans-title-group xml:lang="en"><trans-title>Clinical, morphological and genetic characteristics of young patients with hypertrophic cardiomyopathy with indications for implantable cardioverter-defibrillator</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0233-5555</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Давыдова</surname><given-names>В. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Davydova</surname><given-names>V. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Врач-кардиолог.</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>St. Petersburg</p></bio><email xlink:type="simple">victoria_lp@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0156-8821</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гудкова</surname><given-names>А. Я.</given-names></name><name name-style="western" xml:lang="en"><surname>Gudkova</surname><given-names>A. Ya.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Д.м.н., зав. лабораторией кардиомиопатий НИИ сердечно-сосудистых заболеваний НКИЦ, профессор кафедры терапии факультетской с курсом эндокринологии, кардиологии с клиникой им. Г.Ф. Ланга, в. н. с. Института молекулярной биологии и генетики.</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>St. Petersburg</p></bio><email xlink:type="simple">alexagood-1954@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6897-6171</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Крутиков</surname><given-names>А. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Krutikov</surname><given-names>A. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>К. м.н., в. н. с. НИО инфильтративных заболеваний сердца Института молекулярной биологии и генетики.</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>St. Petersburg</p></bio><email xlink:type="simple">ankrutikov@yandex.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6655-5274</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Полякова</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Poliakova</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>К.м.н., с.н.с. лаборатории кардиомиопатий НИИ сердечно-сосудистых заболеваний НКИЦ, ассистент кафедры терапии факультетской с курсом эндокринологии, кардиологии с клиникой им. Г.Ф. Ланга.</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>St. Petersburg</p></bio><email xlink:type="simple">lica.polyakova@mail.ru</email><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9349-6257</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Костарева</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kostareva</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Д.м.н., директор Института молекулярной биологии и генетики.</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>St. Petersburg</p></bio><email xlink:type="simple">akostareva@hotmail.com</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>СПбГБУЗ Городская больница № 40</institution><country>Россия</country></aff><aff xml:lang="en"><institution>St. Petersburg City Hospital № 40</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ВО Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова Минздрава России; ФГБУ Национальный медицинский исследовательский центр им. В.А. Алмазова Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Pavlov First Saint Petersburg State Medical University; Almazov National Medical Research Center</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГБУ Национальный медицинский исследовательский центр им. В.А. Алмазова Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Almazov National Medical Research Center</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>ФГБОУ ВО Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Pavlov First Saint Petersburg State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>07</day><month>09</month><year>2024</year></pub-date><volume>29</volume><issue>11</issue><fpage>5994</fpage><lpage>5994</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Давыдова В.Г., Гудкова А.Я., Крутиков А.Н., Полякова А.А., Костарева А.А., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Давыдова В.Г., Гудкова А.Я., Крутиков А.Н., Полякова А.А., Костарева А.А.</copyright-holder><copyright-holder xml:lang="en">Davydova V.G., Gudkova A.Y., Krutikov A.N., Poliakova A.A., Kostareva A.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://russjcardiol.elpub.ru/jour/article/view/5994">https://russjcardiol.elpub.ru/jour/article/view/5994</self-uri><abstract><sec><title>Цель</title><p>Цель. Изучить клинические, морфологические и генетические характеристики пациентов молодого возраста с гипертрофической кардиомиопатией (ГКМП), имеющих показания к первичной и вторичной профилактике внезапной сердечной смерти (ВСС).</p></sec><sec><title>Материал и методы</title><p>Материал и методы. В исследование включено 44 пациента молодого возраста с ГКМП, которые обследованы в соответствии с национальными клиническими рекомендациями по ГКМП (2020). Для расчета риска ВСС использовался калькулятор AHA HCM SCD Calculator. Генетическое исследование выполнено с применением целевой панели, включающей 108 генов, ассоциированных с развитием кардиомиопатий.</p></sec><sec><title>Результаты</title><p>Результаты. В исследуемой когорте пациенты молодого возраста в 72,7% случаев (n=32) имели от 1 до 3 факторов кардиометаболического риска (в среднем 1,53±0,8).</p><p>Возраст 18 пациентов, имеющих показания к установке имплантируемого кардиовертера-дефибриллятора (ИКД), варьировался от 18 до 44 лет (28,8±2,2). Возраст на момент установления диагноза составил 18,5±7,4 лет, длительность бессимптомного периода — 6,4±0,9 лет. Расчетный риск ВСС варьировался от 3,11 до 20,71% (6,15 [4,67;7,32]). В 83,3% случаев (n=15) диагностирована семейная форма ГКМП, при этом в 50% (n=9) имел место семейный анамнез ВСС.</p><p>В подгруппе пациентов с показаниями к ИКД генетические варианты с патогенной значимостью (IV и V класс), кодирующие выработку белков саркомера, обнаружены у 6 из 9 пробандов (66,7%).</p><p>Пациентам, которым показан ИКД (n=18), по сравнению с пациентами без таких показаний (n=26) диагноз ГКМП был чаще установлен в детском и подростковом возрасте (61,1% vs 23%, р=0,01). У пациентов, имеющих показания к ИКД, значимо чаще диагностировали паттерн морфологии межжелудочковой перегородки по типу двояковыпуклой (72,2% vs 38,5%, р=0,028). Среди пациентов, имеющих показания к ИКД, доля лиц с низким уровнем физической активности составила 50% (n=9), из них в 55,6% случаев (n=5) была диагностирована избыточная масса тела/ожирение 1 степени.</p></sec><sec><title>Заключение</title><p>Заключение. Детский и подростковый возраст постановки диагноза ГКМП и паттерн морфологии межжелудочковой перегородки по типу двояковыпуклой значимо чаще встречаются у пациентов молодого возраста, имеющих показания к ИКД.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To study the clinical, morphological and genetic characteristics of young patients with hypertrophic cardiomyopathy (HCM) with indications for primary and secondary prevention of sudden cardiac death (SCD).</p></sec><sec><title>Material and methods</title><p>Material and methods. The study included 44 young patients with HCM who were examined in accordance with national clinical guidelines for HCM (2020). The AHA HCM SCD Calculator was used to calculate the risk of SCD. The genetic study was performed using a target panel of 108 genes associated with cardiomyopathies.</p></sec><sec><title>Results</title><p>Results. In the study cohort, young patients in 72,7% of cases (n=32) had from 1 to 3 cardiometabolic risk factors (on average 1,53±0,8).</p><p>The age of 18 patients with indications for implantable cardioverter-defibrillator (ICD) ranged from 18 to 44 years (28,8±2,2). The age at diagnosis was 18,5±7,4 years, while the asymptomatic period lasted 6,4±0,9 years. The estimated risk of SCD ranged from 3,11 to 20,71% (6,15 [4,67; 7,32]). In 83,3% of cases (n=15), familial HCM was diagnosed, while 50% (n=9) had a positive family history of SCD. In the subgroup of patients with indications for ICD, genetic variants with pathogenic significance (class IV and V) encoding the production of sarcomere proteins were detected in 6 of 9 probands (66,7%).</p><p>In patients with indications for ICD (n=18), compared to patients without it (n=26), the diagnosis of HCM was more often established in childhood and adolescence (61,1% vs 23%, p=0,01). In patients with indications for ICD, the reverse curvature hypertrophy of the interventricular septum was significantly more often diagnosed (72,2% vs 38,5%, p=0,028). Among patients with indications for ICD, the proportion of people with low physical activity was 50% (n=9), of which 55,6% (n=5) were diagnosed with overweight/class 1 obesity.</p></sec><sec><title>Conclusion</title><p>Conclusion. Childhood and adolescence at the time of diagnosis of HCM and reverse curvature hypertrophy of the interventricular septum are significantly more common in young patients with indications for ICD.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>гипертрофическая кардиомиопатия</kwd><kwd>внезапная сердечная смерть</kwd><kwd>имплантация кардиовертера-дефибриллятора</kwd><kwd>паттерн морфологии межжелудочковой перегородки</kwd><kwd>патогенные и вероятно патогенные генетические варианты</kwd><kwd>саркомер</kwd></kwd-group><kwd-group xml:lang="en"><kwd>hypertrophic cardiomyopathy</kwd><kwd>sudden cardiac death</kwd><kwd>implantable cardioverter-defibrillator</kwd><kwd>interventricular septum morphology</kwd><kwd>pathogenic and likely pathogenic genetic variants</kwd><kwd>sarcomere</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Sheppard MN, Westaby J, Zullo E, et al. Sudden arrhythmic death and cardiomyopathy are important causes of sudden cardiac death in the UK: results from a national coronial autopsy database. Histopathology. 2023;82(7):1056-66. doi:10.1111/his.14889.</mixed-citation><mixed-citation xml:lang="en">Sheppard MN, Westaby J, Zullo E, et al. Sudden arrhythmic death and cardiomyopathy are important causes of sudden cardiac death in the UK: results from a national coronial autopsy database. Histopathology. 2023;82(7):1056-66. doi:10.1111/his.14889.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC Guidelines for the management of cardiomyopathies: Developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC). European Heart Journal. 2023;44(37):3503-626. doi:10.1093/eurheartj/ehad194.</mixed-citation><mixed-citation xml:lang="en">Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC Guidelines for the management of cardiomyopathies: Developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC). European Heart Journal. 2023;44(37):3503-626. doi:10.1093/eurheartj/ehad194.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Maron MS, Rowin E, Spirito P, et al. Differing strategies for sudden death prevention in hypertrophic cardiomyopathy. Heart. 2023;109(8):589-94. doi:10.1136/heartjnl-2020-316693.</mixed-citation><mixed-citation xml:lang="en">Maron MS, Rowin E, Spirito P, et al. Differing strategies for sudden death prevention in hypertrophic cardiomyopathy. Heart. 2023;109(8):589-94. doi:10.1136/heartjnl-2020-316693.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Ommen SR, Ho CY, Asif IM, et al. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2024 Jun 4;149(23):e1239-e1311. doi:10.1161/CIR.0000000000001250.</mixed-citation><mixed-citation xml:lang="en">Ommen SR, Ho CY, Asif IM, et al. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2024 Jun 4;149(23):e1239-e1311. doi:10.1161/CIR.0000000000001250.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Chumakova OS, Baklanova TN, Milovanova NV, et al. Hypertrophic Cardiomyopathy in Underrepresented Populations: Clinical and Genetic Landscape Based on a Russian Single-Center Cohort Study. Genes (Basel). 2023;14(11):2042. doi:10.3390/genes14112042.</mixed-citation><mixed-citation xml:lang="en">Chumakova OS, Baklanova TN, Milovanova NV, et al. Hypertrophic Cardiomyopathy in Underrepresented Populations: Clinical and Genetic Landscape Based on a Russian Single-Center Cohort Study. Genes (Basel). 2023;14(11):2042. doi:10.3390/genes14112042.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Габрусенко С. А., Гудкова А. Я., Козиолова Н. А. и др. Гипертрофическая кардиомиопатия. Клинические рекомендации 2020. Российский кардиологический журнал. 2021;26(5):4541. doi:10.15829/1560-4071-2021-4541.</mixed-citation><mixed-citation xml:lang="en">Gabrusenko SA, Gudkova AYa, Koziolova NA, et al. 2020 Clinical practice guidelines for Hypertrophic cardiomyopathy. Russian Journal of Cardiology. 2021;26(5):4541. (In Russ.) doi:10.15829/1560-4071-2021-4541.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 2015:5(17):405-24. doi:10.1038/gim.2015.30.</mixed-citation><mixed-citation xml:lang="en">Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 2015:5(17):405-24. doi:10.1038/gim.2015.30.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Marston NA, Han L, Olivotto I, et al. Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy. European Heart Journal. 2021;42(20):1988-96. doi:10.1093/eurheartj/ehab148.</mixed-citation><mixed-citation xml:lang="en">Marston NA, Han L, Olivotto I, et al. Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy. European Heart Journal. 2021;42(20):1988-96. doi:10.1093/eurheartj/ehab148.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Östman-Smith I. What Aspects of Phenotype Determine Risk for Sudden Cardiac Death in Pediatric Hypertrophic Cardiomyopathy? Journal of Cardiovascular Development and Disease. 2022;9(5):124. doi:10.3390/jcdd9050124.</mixed-citation><mixed-citation xml:lang="en">Östman-Smith I. What Aspects of Phenotype Determine Risk for Sudden Cardiac Death in Pediatric Hypertrophic Cardiomyopathy? Journal of Cardiovascular Development and Disease. 2022;9(5):124. doi:10.3390/jcdd9050124.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. European Heart Journal. 2022;43(40):3997-4126. doi:10.1093/eurheartj/ehac262.</mixed-citation><mixed-citation xml:lang="en">Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. European Heart Journal. 2022;43(40):3997-4126. doi:10.1093/eurheartj/ehac262.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Ho CY, Day SM, Ashley EA, et al. Response by Ho et al to Letter Regarding Article, "Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights From the Sarcomeric Human Cardiomyopathy Registry (SHaRe)". Circulation. 2019;139(12):1559-60. doi:10.1161/CIRCULATIONAHA.118.039069.</mixed-citation><mixed-citation xml:lang="en">Ho CY, Day SM, Ashley EA, et al. Response by Ho et al to Letter Regarding Article, "Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights From the Sarcomeric Human Cardiomyopathy Registry (SHaRe)". Circulation. 2019;139(12):1559-60. doi:10.1161/CIRCULATIONAHA.118.039069.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Neubauer S, Kolm P, Ho CY, et al. Distinct Subgroups in Hypertrophic Cardiomyopathy in the NHLBI HCM Registry. Journal of the American College of Cardiology. 2019; 74(19):2333-45. doi:10.1016/j.jacc.2019.08.1057.</mixed-citation><mixed-citation xml:lang="en">Neubauer S, Kolm P, Ho CY, et al. Distinct Subgroups in Hypertrophic Cardiomyopathy in the NHLBI HCM Registry. Journal of the American College of Cardiology. 2019; 74(19):2333-45. doi:10.1016/j.jacc.2019.08.1057.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">He Y, Zhou J. Reversed Septal Curvature Is Associated With Nonsustained Ventricular Tachycardia in Hypertrophic Cardiomyopathy. The American Journal of Cardiology. 2024;210:195-200. doi:10.1016/j.amjcard.2023.10.056.</mixed-citation><mixed-citation xml:lang="en">He Y, Zhou J. Reversed Septal Curvature Is Associated With Nonsustained Ventricular Tachycardia in Hypertrophic Cardiomyopathy. The American Journal of Cardiology. 2024;210:195-200. doi:10.1016/j.amjcard.2023.10.056.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Баланова Ю. А., Шальнова С. А., Деев А. Д. и др. Ожирение в российской популяции — распространенность и ассоциации с факторами риска хронических неинфекционных заболеваний. Российский кардиологический журнал. 2018;(6):123-30. doi:10.15829/1560-4071-2018-6-123-130.</mixed-citation><mixed-citation xml:lang="en">Balanova YuA, Shalnova SA, Deev AD, et al. Obesity in the Russian population is the prevalence and association with risk factors for chronic non-communicable diseases. Russian Journal of Cardiology. 2018;(6):123-30. (In Russ.) doi:10.15829/1560-4071-2018-6-123-130.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Ватутин Н. Т., Склянная Е. В. Распространенность артериальной гипертензии и факторов риска у лиц молодого возраста. Архив внутренней медицины. 2017;7(1):30-4. doi:10.20514/2226-6704-2017-7-1-30-34.</mixed-citation><mixed-citation xml:lang="en">Vatutin NT, Sklyanna EV. Prevalence of arterial hypertention and risk factors in young adults. The Russian Archives of Internal Medicine. 2017;7(1):30-4. (In Russ.) doi:10.20514/2226-6704-2017-7-1-30-34.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Lampert R, Ackerman MJ, Marino BS, et al. Vigorous exercise in patients with hypertrophic cardiomyopathy. JAMA Cardiology. 2023;8(6):595-605. doi:10.1001/jamacardio.2023.1042.</mixed-citation><mixed-citation xml:lang="en">Lampert R, Ackerman MJ, Marino BS, et al. Vigorous exercise in patients with hypertrophic cardiomyopathy. JAMA Cardiology. 2023;8(6):595-605. doi:10.1001/jamacardio.2023.1042.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
